Novartis Increases 2030 Growth Projections Despite Analysts' Concerns About Patent Threats

Bitget App

Trade smarter

Bitget

News

Markets

Novartis Increases 2030 Growth Projections Despite Analysts' Concerns About Patent Threats

Bitget-RWA2025/11/23 20:30

By:Bitget-RWA

- Novartis raised 2030 sales growth targets to 5-6% annually, driven by high peak sales expectations for oncology drugs Kisqali and Scemblix. - CEO Vas Narasimhan highlighted eight de-risked drugs with $3-10B peak potential, but analysts warned of patent expirations and uncertain pipeline progress beyond 2030. - Shares rose 0.5% post-announcement, while Exact Sciences surged 17% on its $105/share acquisition by Abbott and Samsung Biologics saw a 71% valuation re-rating after spin-off. - J.P. Morgan caution

Swiss pharmaceutical leader

Novartis AG

(NOVN.SW) has updated its medium-term revenue outlook,

projecting annual sales growth of 5% to 6% in constant currency through 2030

, fueled by higher anticipated peak sales for its flagship oncology treatments Kisqali and Scemblix. This revised forecast,

shared at a management meeting in London

, signals the company’s optimism in its product lineup even as major drugs like Cosentyx and Entresto approach patent expiration. CEO Vas Narasimhan highlighted the robustness of Novartis’s development pipeline, which features eight lower-risk drugs each with peak sales potential between $3 billion and $10 billion, along with more than 30 promising candidates in advanced development.

Experts remain split on whether Novartis can maintain this growth trajectory. While

Stefan Schneider of Vontobel commended

the company for reliably meeting its goals and raising its peak sales forecasts for Kisqali (now $10 billion) and Scemblix ($4 billion), J.P. Morgan pointed to challenges from patent cliffs and uncertainties in the drug pipeline after 2030. The bank

observed that reaching $72.4 billion in sales by 2030

will depend on strong clinical trial outcomes and regulatory green lights. Following the news, shares of

Novartis

gained 0.5%,

bringing the stock’s year-to-date increase to 16%

Pre-market trading in the pharmaceutical industry was mixed.

Novartis Increases 2030 Growth Projections Despite Analysts' Concerns About Patent Threats image 0

Exact Sciences jumped more than 17%

after Abbott Laboratories announced plans to buy the liquid biopsy company for $105 per share. At the same time, Super Micro Computer (SMCI) rose over 5% after unveiling new GPU systems that use AMD’s Instinct MI355X chips.

Samsung Biologics, a contract development and manufacturing organization (CDMO) based in South Korea, is set for further expansion after spinning off its biosimilar business.

Analyst Yisoo Jeong from IBK Securities believes

that this move could help attract additional CDMO deals by easing clients’ worries about their intellectual property being exposed to Samsung’s own drug development. According to the analyst, the change

has led to a 71% upward revision

in the company’s valuation.

Novartis’s new outlook also highlighted the significance of its upcoming milestones. The company anticipates more than 15 pivotal readouts over the next two years,

including results from advanced-stage cancer and rare disease studies

. Still,

J.P. Morgan warned that pricing challenges

for Kisqali in the U.S. could become an obstacle, especially if the drug is subject to Medicare price negotiations.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

PoolX: Earn new token airdrops

Lock your assets and earn 10%+ APR

Lock now!

- OKX's Zcash relisting triggered a 12% price surge to $600, outpacing Bitcoin amid U.S. regulatory easing. - Analysts debate Zcash's role: Balchunas warns it splits institutional Bitcoin support, while Van Eck calls it essential privacy complement. - Zcash's quantum-resistant upgrades and $9.24B market cap highlight growing institutional interest despite maximalist skepticism. - Winklevoss twins' Cypherpunk Tech and SEC's regulatory shift signal privacy protocols' rising acceptance in crypto mainstream.

Bitget-RWA•2025/11/23 21:20

Zcash News Today: Zcash's Return to Exchanges Reignites Discussion on 'Third-Party' Privacy in Crypto

Devices with Extended Lifespans Enhance Sustainability but Reduce Productivity

- Americans now keep smartphones for 29 months (up from 22 in 2016), driven by cost-cutting and sustainability, but this trend slows productivity as outdated devices struggle with modern demands. - Federal Reserve data shows each delayed equipment upgrade reduces productivity by 0.33%, while experts warn aging tech causes systemic inefficiencies through throttled networks and outdated software. - Solutions like modular upgrades and circular economies aim to balance sustainability with functionality, yet ri

Bitget-RWA•2025/11/23 21:20

Devices with Extended Lifespans Enhance Sustainability but Reduce Productivity

Bitcoin Updates Today: Gemini Introduces Bitcoin Card: Incentivizing Users to Connect Cryptocurrency with Everyday Purchases

- Gemini launches Bitcoin credit card with referral rewards and cashback to bridge crypto and traditional finance. - Market analysis shows mid-cycle holders driving Bitcoin's 12% selloff below $90,000 amid oversold futures conditions. - Crypto cards differ from traditional offerings by enabling direct Bitcoin spending without fiat conversion, addressing user accessibility challenges. - Experts like Saylor and Winklevoss highlight Bitcoin's reduced volatility and potential for recovery, positioning crypto a

Bitget-RWA•2025/11/23 21:04

Bitcoin Updates Today: Gemini Introduces Bitcoin Card: Incentivizing Users to Connect Cryptocurrency with Everyday Purchases

Ethereum Updates: Yi Lihua's Careful Buying Strategy Stands Out Amid Ethereum's Sharp Downturn

- Yi Lihua, Liquid Capital founder, accumulates Ethereum in $3,000–$3,300 range via spot buys, avoiding leverage amid volatile market conditions. - Ethereum faces $689M outflows, rising leverage ratios (0.5617), and $47.59B exchange reserves, signaling heightened bearish caution. - Macroeconomic factors like Fed hawkishness and 4.08% 10-year yields drive capital outflows, pushing Ethereum down 6.5% to $3,080 weekly. - Yi's low-risk accumulation contrasts with $29.23M long liquidations, positioning him to c

Bitget-RWA•2025/11/23 21:04